Fifteen startups — with clean energy solutions involving everything from solar energy to hydrogen — are joining Rice Alliance's Clean Energy Accelerator later this summer. Photo via Getty Images

A clean energy program has announced its third cohort and named the 15 startups that were accepted into to the accelerator.

The Rice Alliance's Clean Energy Accelerator revealed its 2023 cohort that will be in the 10-week program that kicks of July 25. CEA, a hybrid program based out of the Ion, will wrap up with a Demo Day alongside the 20th Annual Rice Alliance Energy Tech Venture Forum on September 21.

The accelerator, led by Kerri Smith and Matt Peña, provides the cohort with programming, networking, and mentorship from six executives in residence — Nathan Ball, Fatimah Bello, Michael Egan, Michael Evans, Stephen Sims, and Deanna Zhang.

Since the Clean Energy Accelerator launched in 2021, the program has supported 29 ventures that have gone on to raise over $75 million in funding, identified and launched pilots, and created jobs, According to Rice, many of these companies relocated to Houston.

Class 3, which has already raised $23.3 million in funding, hails from four countries and seven states and are addressing a range of energy solutions — from advanced materials, carbon management/capture, energy storage, hydrogen, solar energy, wind energy, and more. They were selected by a screening committee consisting of more than 50 industry experts, investors, energy leaders, and entrepreneurs.

The third class, as announced by Rice Alliance, is as follows:

  • Ayrton Energy, based in Alberta, Canada, provides hydrogen storage technology that improves hydrogen transport logistics for distributed energy applications.
  • Headquartered in Massachusetts, Carbix transforms atmospheric carbon dioxide emissions into building materials using proprietary reactor technology.
  • Houston-based CryoDesalination lowers the carbon footprint and cost of removing salts and heavy metals from water and industrial effluents.
  • Digital Carbon Bank, based in Alberta, Canada, provides a carbon solution tailored for the energy industry.
  • Chandler, Arizona-based EarthEn provides compressed carbon dioxide-based energy storage and artificial intelligence solutions allowing grid owners/operators to be completely renewable.
  • H Quest Vanguard, from Pittsburgh, provides green hydrogen at a five to 10 times lower cost to users of natural gas to decarbonize industrial heat.
  • Calgary, Alberta-based Highwood Emissions Management's SaaS platform allows oil and gas companies to understand their emissions and develop robust plans to reduce them.
  • Icarus RT, from San Diego, California, improves photovoltaic efficiency while enabling useful heat energy storage.
  • Los Altos, California-based Khepra has developed a chemical manufacturing platform for the low-cost, sustainable production of agrochemicals.
  • Binghamton, New York-based Natrion’s electrolyte is a drop-in solid-state battery component that can be rapidly implemented into existing batteries.
  • Oceanways, based in London, provides low-cost, flexible and scalable zero-emission underwater "virtual pipelines" to energy producers.
  • Relyion Energy, from Santa Clara, California, is developing battery usage and intelligence solutions with deeper data and insights for retired electric vehicle batteries.
  • Massachusetts-based Triton Anchor provides a more cost-effective anchoring solution for offshore clean energy with minimal environmental impact.
  • TROES, from Markham, Ontario, provides a 4-in-1 microgrid solution with integrated hardware and software for a streamlined energy storage experience.
  • Mexico City-based Tycho Solutions supports clean energy project developers by saving time and money during the critical project-siting process.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”